Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Medicamen Biotech Ltd (MEDICAMEQ)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531146 NSE: MEDICAMEQ Pharmaceuticals & Drugs | Small Cap | Medicamen Biotech Share Price
₹328.95 14.55 (4.63%)
As on 22-Sep'26 12:13
Medicamen Biotech Ltd (MEDICAMEQ)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531146 NSE: MEDICAMEQ Pharmaceuticals & Drugs | Small Cap | Medicamen Biotech Share Price
₹328.95 14.55 (4.63%)
As on 22-Sep'26 12:13
Key Metrics
Valuation Multiples
Market Cap
₹426 Cr.
Current Price
₹329
52-Week Low / High
₹210 / 454
TTM EPS
₹8
TTM Sales
₹203 Cr.
Book Value per Share
₹199.5
P/E Ratio
39.38
Lower than its 5-year historical median
Industry PE
55.1
Price to Book (P/B)
1.58
Lower than its 5-year historical median
Price to Sales (P/S)
2.10
Lower than its 5-year historical median
EV/EBITDA
19.43
Lower than its 5-year historical median
Dividend Yield
0.3%
Profitability Efficiency
Return on Equity (ROE)
3.23%
Underperforms industry median
Return on Capital Employed (ROCE)
5.77%
Underperforms industry median
Return on Assets (ROA)
2.24%
Operating Profit Margin
8.9%
Net Profit Margin
4.03%
Gross Profit Margin
10.4%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-12.14%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-38.66%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-30.87%
Asset Quality
Promoter Holding
40.46%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹256 Cr.
Equity
₹13.6 Cr.
Face Value
₹10
All Time Low / High
₹2.25 / 1219.00
Check Before You Invest
Quality
Not GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Strong
Is Medicamen Biotech Ltd a good quality company?
Medicamen Biotech Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Medicamen Biotech Ltd performance compare with that of its Peers?
Revenue growth of Medicamen Biotech Ltd vs industry peers?
Medicamen Biotech Ltd revenue CAGR is 5.31%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Medicamen Biotech Ltd?
Promoters hold 40.46% of the Medicamen Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Medicamen Biotech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 5.9% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Medicamen Biotech Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11.4% | 24.1% | 24.9% | 20.2% | 15.3% | 13.1% | 12.8% | 11% | 10.1% | 7% | - |
| Value Creation Index ⓘ | -0.2 | 0.7 | 0.8 | 0.4 | 0.1 | -0.1 | -0.1 | -0.2 | -0.3 | -0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 67.3 | 82.5 | 112 | 123 | 117 | 110 | 115 | 138 | 172 | 151 | 184 |
| Sales YoY Gr. | - | 22.6% | 35.2% | 10% | -4.3% | -6.1% | 4.8% | 19.4% | 25% | -12.1% | - |
| Adj EPS ⓘ | 0.1 | 4.8 | 7.7 | 8.8 | 9.2 | 10 | 11.4 | 11 | 9.7 | 7 | 7.6 |
| YoY Gr. | - | 4650% | 62.5% | 14.1% | 4.8% | 7.8% | 14.3% | -2.9% | -12.5% | -27.1% | - |
| BVPS (₹) ⓘ | 17.9 | 24.7 | 63.7 | 73.7 | 98.6 | 104.5 | 114.8 | 146.8 | 159.3 | 166 | 203.2 |
| Adj Net Profit ⓘ | 0.1 | 5 | 9 | 10.3 | 11.3 | 12.2 | 13.9 | 14 | 12.3 | 9 | 10 |
| Cash Flow from Ops. ⓘ | 6.2 | 3.6 | -5.5 | 4.3 | 11.7 | 13 | 4.8 | -3.5 | -0.3 | -2.6 | - |
| Debt/CF from Ops. ⓘ | 3.3 | 4.9 | -2.7 | 2.7 | 1 | 1.5 | 5.4 | -7.4 | -121.1 | -10.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 9.4% | 5.2% | 9.5% | -12.1% | ||||
| Adj EPS ⓘ | 60.4% | -5.3% | -14.8% | -27.1% | ||||
| BVPSⓘ | 28.1% | 11% | 13.1% | 4.2% | ||||
| Share Price | 6.4% | -11.5% | -20.9% | 2.2% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.6 | 22.4 | 17.8 | 12.8 | 10.8 | 9.5 | 9.8 | 8.2 | 6.1 | 4.2 | 4.1 |
| Op. Profit Mgn % ⓘ | 8.2 | 14.1 | 15.1 | 14.3 | 15.5 | 18.2 | 20.9 | 17.9 | 15.8 | 11.3 | 10.3 |
| Net Profit Mgn % ⓘ | 0.2 | 6.1 | 8.1 | 8.4 | 9.6 | 11 | 12 | 10.1 | 7.1 | 5.9 | 5.6 |
| Debt to Equity ⓘ | 1.1 | 0.7 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | - |
| Working Cap Days ⓘ | 230 | 197 | 196 | 235 | 287 | 310 | 332 | 358 | 342 | 431 | 196 |
| Cash Conv. Cycle ⓘ | 42 | 37 | 64 | 74 | 71 | 66 | 88 | 128 | 118 | 173 | 123 |
Valuation of Medicamen Biotech - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|
| Sales | 123 | 126 | 113 | 115 | 141 | 179 | 163 |
| Operating Expenses ⓘ + | 105 | 106 | 93 | 91 | 117 | 156 | 148 |
| Operating Profit ⓘ | 17 | 19 | 20 | 24 | 24 | 24 | 14 |
| Operating Profit Margin (%) | 14.2% | 15.5% | 17.5% | 20.9% | 17.3% | 13.1% | 8.9% |
| Other Income ⓘ + | 4 | 2 | 1 | 2 | 2 | 2 | 6 |
| Interest ⓘ | 1 | 1 | 2 | 2 | 3 | 6 | 4 |
| Depreciation ⓘ | 2 | 2 | 3 | 6 | 6 | 7 | 7 |
| Profit Before Tax ⓘ | 18 | 18 | 16 | 18 | 17 | 13 | 10 |
| Tax ⓘ | 5 | 5 | 4 | 3 | 2 | 4 | 3 |
| Profit After Tax | 12 | 13 | 12 | 15 | 15 | 9 | 7 |
| PAT Margin (%) | 9.8% | 10.6% | 10.8% | 12.9% | 10.5% | 5.3% | 4.0% |
| Adjusted EPS (₹) | 10.3 | 10.9 | 9.9 | 12.2 | 11.6 | 7.5 | 5.2 |
| Dividend Payout Ratio (%) | 9.70% | 4.60% | 10.10% | 8.20% | 8.60% | 13.40% | 19.40% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 87 | 121 | 133 | 146 | 191 | 207 | 213 | ||||
| Debt + | 12 | 10 | 17 | 24 | 24 | 31 | 33 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Trade Payables | 31 | 37 | 32 | 43 | 48 | 39 | 43 | ||||
| Others Liabilities ⓘ | 8 | 13 | 12 | 11 | 14 | 15 | 5 | ||||
| Total Liabilities ⓘ | 137 | 181 | 194 | 225 | 277 | 292 | 294 | ||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 24 | 34 | 90 | 92 | 93 | 92 | 87 | ||||
| CWIP ⓘ | 15 | 40 | 0 | 0 | 0 | 0 | 0 | ||||
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Inventories | 15 | 17 | 5 | 27 | 45 | 59 | 62 | ||||
| Trade Receivables | 43 | 50 | 53 | 63 | 65 | 55 | 69 | ||||
| Cash Equivalents | 9 | 3 | 4 | 4 | 21 | 15 | 4 | ||||
| Others Assets ⓘ | 30 | 37 | 43 | 39 | 53 | 71 | 72 | ||||
| Total Assets ⓘ | 137 | 181 | 194 | 225 | 277 | 292 | 294 | ||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 4 | 13 | 13 | 4 | -6 | -7 | -8 |
| Cash Flow From Investing Activity ⓘ + | -15 | -37 | -18 | -8 | -6 | -6 | -1 |
| Cash Flow From Financing Activity ⓘ + | -4 | 19 | 6 | 4 | 29 | 6 | -1 |
| Net Cash Flow ⓘ | -14 | -5 | 1 | -0 | 17 | -6 | -11 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 13.95 | 12.94 | 9.89 | 11.25 | 9.13 | 4.94 | 3.23 | |||
| ROCE (%) | 19.3 | 16.54 | 12.99 | 12.94 | 10.85 | 8.46 | 5.77 | |||
| Asset Turnover Ratio | 0.9 | 0.79 | 0.6 | 0.55 | 0.56 | 0.63 | 0.55 | |||
| PAT to CFO Conversion(x) | 0.33 | 1 | 1.08 | 0.27 | -0.4 | -0.78 | -1.14 | |||
| Working Capital Days | ||||||||||
| Receivable Days | 129.10 | 135.70 | 166 | 183 | 166.50 | 122.70 | 139.40 | |||
| Inventory Days | 45.40 | 46.90 | 35.90 | 50.90 | 93.40 | 106.30 | 136.40 | |||
| Payable Days | 161.10 | 189 | 253.70 | 316.70 | 311.50 | 215.80 | 226.10 | |||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Medicamen Biotech Ltd FAQs
The current trading price of Medicamen Biotech on 22-Sep-2026 12:13 is ₹328.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Medicamen Biotech stood at ₹426.4 Cr
The latest P/E ratio of Medicamen Biotech as of 21-Sep-2026 is 41.39.
The latest P/B ratio of Medicamen Biotech as of 21-Sep-2026 is 1.55.
The 52-week high of Medicamen Biotech is ₹454.0 and the 52-week low is ₹210.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Medicamen Biotech is ₹184 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Medicamen Biotech Ltd is a below average quality company.
The key valuation ratios of Medicamen Biotech Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Medicamen Biotech Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Medicamen Biotech Ltd
Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.
Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.
In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.
In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.
Product range of the company includes:
The company is the Manufacturer and supplier of Comprehensive range of products:
- Tablets
- Capsules
- Liquid Syrup
- Dry Syrup (Beta Lactum and Non Beta Lactum)
- Ointment
- ORS
Achievements/ recognition:
The company is the receipents of the following certificates & awards:
- WHO-GMP
- ISO 9001: 2000
- Star Export House
- Certificate Of Merit
- “Niryat Shree†for the four consecutive years from 2002 to 2005 from Government of India
You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
